937263-81-5
Chemical Structure
ONT-993
Synonym(s): AR 00440993
- CAS No.: 937263-81-5
- Formula:C26H24N8O3
- Molecular Weight:496.52
IUPAC Name: N-(7-(dimethylamino)-10-(2-(2-hydroxyethyl)-5-(2-(((3-(4-(6-(4-methylpiperazin-1-yl)-1H,3'H-[2,5'-bibenzo[d]imidazol]-2'-yl)phenoxy)propyl)carbamoyl)oxy)ethyl)phenyl)-5,5-dimethyldibenzo[b,e]silin-3(5H)-ylidene)-N-methylmethanaminium 2,2,2-trifluoroacetate
InChIKey: TWEMIPSDKADNMC-UHFFFAOYSA-N
SMILES: OCC1(C)N=C(NC2=CC3=C(NC4=CC=C(C(C)=C4)OC5=CC6=NC=NN6C=C5)N=CN=C3C=C2)OC1
Biological Activity: ONT-993 (AR 00440993) is a metabolite of Tucatinib (HY-16069). Tucatinib is a potent, orally active, selective HER2 inhibitor. ONT-993 can be used in research on HER2-positive breast cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ONT-993 | 99.85% | ONT-993 (AR 00440993) is a metabolite of Tucatinib (HY-16069). Tucatinib is a potent, orally active, selective HER2 inhibitor. ONT-993 can be used in research on HER2-positive breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Murthy RK, et al. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2 breast cancer: TBCRC049 phase 2 study results. Nature cancer. 2026 Mar;7(3):424-434.
- [2]. Metzger Filho O, et al. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Annals of Oncology. 2020 Sep 1;31(9):1231-9.
- [3]. Yan F, et al. Response of leptomeningeal metastasis of breast cancer with a HER2/neu activating variant to tucatinib: a case report. Journal of the National Comprehensive Cancer Network. 2022 Apr 11;20(7):745-52.
- [4]. Shagisultanova E, et al. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Dec 15;29(24):5021-5030.
